Novel artificial protein catalysts

Engineered protein catalysts, utilizing human serum albumin to house metal catalysts in hydrophobic pockets, address the vulnerability of existing catalysts to biological substances, ensuring effective in vivo applications.

JP7578987B2Active Publication Date: 2024-11-07GLYTECH LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2021522230
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-05-24
Filing Date
2020-05-18
Publication Date
2024-11-07
Estimated Expiration
2040-05-18

AI Technical Summary

Technical Problem

Existing catalysts for in vivo synthetic chemical therapy are vulnerable to biological substances, particularly thiol-containing glutathione, leading to rapid inactivation, and there is a lack of effective studies in mammalian models.

Method used

Development of engineered protein catalysts, such as those using human serum albumin (HSA) to house metal catalysts like ruthenium in hydrophobic binding pockets, protecting them from biological agents and maintaining catalytic activity.

Benefits of technology

The engineered protein catalysts provide protection from biological substances, maintaining catalytic activity and enabling targeted in vivo applications, including selective cell tagging and biosensing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007578987000011
    Figure 0007578987000011
  • Figure 0007578987000012
    Figure 0007578987000012
  • Figure 0007578987000013
    Figure 0007578987000013
Patent Text Reader

Abstract

[Problem] To provide a novel artificial protein catalyst that enables the protection of a catalyst from substances in vivo and has potential usefulness in therapeutic in vivo synthetic chemistry. [Solution] Provided is a complex of a protein and a catalyst selected from a metallic catalyst and an organic catalyst. In the complex according to the present invention, the protein is a protein having a hydrophobic spot in the three-dimensional structure thereof and the catalyst is housed in the hydrophobic spot so that the catalyst is not or substantially not exposed to a hydrophilic environment. 
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to a novel artificial protein catalyst. [Background technology]

[0002] Currently, attempts are being made to use catalysts in "in vivo synthetic chemistry therapy." In vivo synthetic chemistry therapy is based on the concept of introducing inactive and non-toxic raw materials or reagents into the body, activating the raw materials or reagents with a catalyst at a specific location in the body, and exerting an effect. In this context, there is growing interest in the development of new catalysts that can be used for therapy (Non-Patent Document 1).

[0003] One of the barriers in the development of such catalysts is the protection of the catalyst from biological substances. For example, it is known that metalloenzymes such as gold (Au), palladium (Pd), and ruthenium (Ru) are rapidly inactivated when exposed to the thiol-containing glutathione (GSH), which is present in the range of 0.5-10 mM in cells and approximately 2-20 μM in plasma.

[0004] To date, most studies have only examined catalysis in cells or non-mammalian models such as zebrafish, either via artificial metalloenzymes or metal catalytic complexes (Non-Patent Documents 2-17). [Prior art documents] [Non-patent literature]

[0005] [Non-Patent Document 1] Rebelein,JG;Ward,TRCurr.Opin.Biotechnol.2018,53,106-114. [Non-Patent Document 2] Miller, MA;Askevold,B.;Mikula,H.;Kohler,RH;Pirovich,D.;Weissleder,R.Nat.Commun.2017,8,15906.

Table 3

Fashion 4

Wood 5

Wood 6

Waterfall 7

Waterfall 8

Outdoor Tools9

Outdoor Tools 10

Outdoor Content11

Outdoor Tools 12

Outdoor Tools13

Outdoor Tools 14

Outdoor Tools 15

[0006] The present invention aims to provide novel artificial protein catalysts that enable protection of the catalyst from biological substances and have potential utility for in vivo synthetic chemistry therapy. [Means for solving the problem]

[0007] Human serum albumin (HSA) is a 66.5kDa protein abundant in plasma, with a half-life in serum of approximately 19 days (Peters, T., Jr. Adv. Protein Chem. 1985, 37, 161-245.). HSA is known to be a carrier protein for various hormones, fatty acids, and small molecule drugs, and it has been confirmed that HSA has multiple major and minor binding sites for various ligands (Ghuman, J.; Zunszain, PA; Petitpas, I.; Bhattacharya, AA; Otagiri, M.; Curry, SJ Mol. Biol. 2005, 353, 38-52.).

[0008] In order to design a biocompatible artificial protein catalyst, the present inventors selected HSA as a protein and investigated accommodating a metal catalyst in the hydrophobic binding pocket of HSA. They then used ruthenium, a metal catalyst, as a catalyst and immobilized the metal catalyst on albumin drug binding site I, which is known to bind (interact) with coumarin derivatives (such as warfarin), and found that the catalytic activity of the bound ruthenium could be protected even in the presence of 20 mM GSH under in vitro conditions, thus completing the present invention.

[0009] That is, the present invention includes the following features: [1] A complex of a protein and a catalyst selected from a metal catalyst and an organic catalyst, The protein has a hydrophobic spot in its three-dimensional structure, the composite contains the catalyst within the hydrophobic spot such that the catalyst is not exposed or substantially not exposed to a hydrophilic environment; Complex.

[0010] [2] The complex according to [1], The protein is a natural or artificial protein. Complex.

[0011] [3] The complex according to [1] or [2], The protein is selected from the group consisting of human serum albumin (HSA), immunoglobulin G (IgG), immunoglobulin A (IgA), transferrin, antitrypsin, haptoglobin, α1-acid glycoprotein, myoferlin, Trk receptor, estrogen receptor, and folate receptor. Complex.

[0012] [4] The complex according to any one of [1] to [3], The metal catalyst is selected from the group consisting of boron catalyst, magnesium catalyst, aluminum catalyst, silicon catalyst, calcium catalyst, scandium catalyst, titanium catalyst, vanadium catalyst, chromium catalyst, manganese catalyst, iron catalyst, cobalt catalyst, nickel catalyst, copper catalyst, zinc catalyst, yttrium catalyst, zirconium catalyst, niobium catalyst, molybdenum catalyst, ruthenium catalyst, rhodium catalyst, palladium catalyst, silver catalyst, indium catalyst, tin catalyst, barium catalyst, hafnium catalyst, tungsten catalyst, rhenium catalyst, osmium catalyst, iridium catalyst, platinum catalyst, gold catalyst, and lanthanoid Lewis acid catalyst. Complex.

[0013] [5] The complex according to [4], The lanthanide Lewis acid catalyst is selected from the group consisting of yttrium catalysts, lanthanum catalysts, cerium catalysts, samarium catalysts, europium catalysts, gadolinium catalysts, terbium catalysts, thulium catalysts, and lutetium catalysts. Complex.

[0014] [6] The complex according to any one of [1] to [5], the protein is human serum albumin, The catalyst is a metal catalyst. Complex.

[0015] [7] The complex according to [6], The metal catalyst is a ruthenium catalyst. Complex.

[0016] [8] The complex according to [6] or [7], The hydrophobic spot of human serum albumin is albumin drug binding site I; Complex.

[0017] [9] The complex according to any one of [6] to [8], The metal catalyst is bound to the hydrophobic spot via a ligand for human serum albumin. Complex.

[0018]

[10] The complex according to [9], The ligand is selected from the group consisting of warfarin, azapropazone, acenocoumarol, phenylbutazone, salicylates, indomethacin, phenytoin, tolbutamide, chlorpropamide, iofenoxate, iodipamide, sulfadimethoxine, fenoproxomone, glibenclamide, sulfathiazole, tenoxicam, camptothecin, valsidendeazid, anderelatan, diadereal, anderelatan, diadereal, anderelatan, diaderealtan, prodan, bilirubin, eicosanoids, and carboxy-methyl-propyl-furanpropanoate (a uremic toxin), and coumarin; Complex.

[0019]

[11] The complex according to [9] or

[10] , The metal catalyst is bound to the hydrophobic spot via a linker attached to the ligand. Complex.

[0020]

[12] The conjugate according to

[11] , The linker is an alkyl chain or a polyethylene glycol (PEG) chain having an amino group and a carboxyl group at both ends. Complex.

[0021]

[13] The conjugate according to

[12] , The linker is C 1 ~C 3 Alkyl or PEG chain with degree of polymerization 1-3 Complex.

[0022]

[14] The complex according to any one of [1] to

[13] , The surface of the protein is modified to interact with a target site in vivo. Complex.

[0023]

[15] The conjugate according to

[14] , The modification is a modification with a sugar chain. Complex.

[0024]

[16] The complex according to any one of [1] to

[13] , The protein further comprises a portion that interacts with a target site in vivo. Complex.

[0025]

[17] The conjugate according to

[14] or

[15] , The protein is human serum albumin. Complex.

[0026]

[18] A composition comprising a complex described in any one of [1] to

[17] .

[0027]

[19] The composition described in

[18] , which is a pharmaceutical composition further comprising a pharma- ceutically acceptable carrier.

[0028]

[20] The composition according to

[19] , Used in combination with a prodrug that can be activated by the complex, composition.

[0029]

[21] The composition according to

[19] , further comprising a prodrug that can be activated by said complex, composition.

[0030]

[22] The composition according to

[19] , Used to selectively tag specific cells, composition.

[0031]

[23] The composition according to

[22] , administered in combination with a chemical entity that tags the cells; composition.

[0032]

[24] The composition according to

[18] , Used as a biosensor composition.

[0033]

[25] The composition according to

[18] , Used as a biosensor to detect ethylene, composition.

[0034]

[26] A pharmaceutical composition comprising a prodrug, The prodrug can be activated by the complex according to any one of [1] to

[17] , The pharmaceutical composition is used in combination with a complex according to any one of [1] to

[17] . Pharmaceutical compositions.

[0035]

[27] A combination medicine comprising: A first drug comprising the complex according to any one of [1] to

[17] ; a second drug comprising a prodrug that can be activated by the complex; A combination medicine comprising:

[0036] It will be understood by those skilled in the art that any combination of one or more of the features of the present invention described above is also within the scope of the present invention. Effect of the Invention

[0037] According to the present invention, a novel artificial protein catalyst is provided which enables protection of the catalyst from biological substances. [Brief description of the drawings]

[0038] [Figure 1] FIG. 1 shows the fluorescence assay results of the products obtained by reacting the ruthenium catalyst Ru1-3,6 with HSA. [Diagram 2]FIG. 2 shows the saturation binding curves for the reaction of HSA with warfarin or ibuprofen followed by reaction with the ruthenium catalysts Ru1-3,6. [Diagram 3] FIG. 3 shows an experimental system used in the present Examples for testing the catalytic ability of the alb-Ru complex. [Figure 4] FIG. 4 shows the evaluation results of the catalytic ability of the alb-Ru complex under different conditions. [Diagram 5] FIG. 5 shows the evaluation results of the catalytic ability of the alb-Ru complex under different conditions. [Figure 6] FIG. 6 shows the Michaelis-Menten kinetic parameters of substrates 1a-e in the presence or absence of GSH for ArM activity (artificial metalloenzyme activity). [Figure 7] FIG. 7 shows molecular modeling of the ruthenium catalyst Ru1-3,6 docked to human serum albumin (PDB: 1H9Z). [Figure 8] FIG. 8 shows the results of cell imaging demonstrating that GArM-Ru1(2,3-Sia) accumulates well in SW620 human colon adenocarcinoma cells. [Figure 9] FIG. 9 shows a comparison of the accumulation of GArM-Ru1(2,3-Sia) among SW620 human colon adenocarcinoma cells, HeLa human cervical carcinoma-derived cells, and A549 human alveolar basal epithelial adenocarcinoma cells. [Figure 10] FIG. 10 shows kinetic experiments on the activation of prodrugs 1g and 1h by the GArM-Ru complex. [Figure 11] FIG. 11 shows a comparison of the cell proliferation inhibitory effects of a prodrug, a prodrug and alb-Ru1, or a prodrug and GArM-Ru1 on cancer cell lines. [Figure 12] FIG. 12 shows the synthesis scheme of the ArM ethylene probe (AEP). [Figure 13] FIG. 13 shows the observed fluorescence intensity of the alb-Ru compound compared to the AEP probe. [Figure 14]FIG. 14 shows a comparison of CD spectra to investigate the folding changes of various protein compounds in this study. [Figure 15] Figure 15 shows the results of monitoring the changes in ethylene production in various organelles (outer pericarp, locules, and columella) at different developmental stages (unripe and ripe) of kiwifruit using AEP. The number of samples was outer pericarp (n=24), locules (n=2), and columella (n=4). Statistical analysis was performed using paired sample t-test. *P<0.03, **P<0.002, ***P<0.0002, ****P<0.0001, ns=non-significant. [Figure 16] Figure 16 shows the fluorescence intensity of the epidermis of wild-type Col-0(b) treated with AEP (100 μM) and images captured by bright-field microscopy (40x magnification), as well as the results detected by further adding ACC (1 mM), an ethylene biosynthesis promoter. [Figure 17] Figure 17 shows the amount of ethylene produced by Arabidopsis thaliana after addition of ACC, as observed by fluorescence intensity. All values ​​were obtained from triplicate experiments. Statistical analysis was performed using one-way ANOVA with Tukey's multiple comparison test. *P<0.03, **P<0.002, ***P<0.0002, ****P<0.0001, ns=non-significant part. [Figure 18] FIG. 18 shows a comparison of flow cytometry results of HeLa cells treated with and without GArM. [Figure 19] FIG. 19 shows a comparison of the flow cytometry results between mouse peritoneal cavity-derived macrophages treated with GArM and those not treated with GArM. [Figure 20] Figure 20 shows a comparison of flow cytometry results for HeLa cells and mouse peritoneal macrophages treated with GArM and HeLa cells and mouse peritoneal macrophages not treated with GArM. Note that the Q3 values ​​in the upper left and lower left figures are 99.09% and 43.06%, respectively. [Figure 21] FIG. 21 shows the results of the cell adhesion assay carried out in Example 8. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0039] The present invention relates to a novel artificial protein catalyst. Specifically, the artificial protein catalyst according to the present invention is a complex of a protein and a catalyst selected from a metal catalyst or an organic catalyst (hereinafter, also referred to as the "complex of the present invention").

[0040] The complex of the present invention can be characterized by a configuration in which a catalyst is accommodated in a hydrophobic spot of a protein having a hydrophobic spot in its three-dimensional structure so that the catalyst is not exposed or substantially not exposed to a hydrophilic environment. That is, the complex of the present invention can protect the catalyst from biological substances by preventing exposure or substantial exposure of the catalyst to a hydrophilic environment. The complex of the present invention may accommodate the catalyst in only one of the hydrophobic spots present in the protein, or in multiple (or all) of the hydrophobic spots.

[0041] The complex of the present invention can also be characterized by having a configuration that avoids exposure or substantial exposure of the catalyst to a hydrophilic environment, while still being capable of promoting a target reaction of the catalyst, i.e., in a preferred embodiment, the complex of the present invention can exert a desired activity in vivo while protecting the catalyst from biological substances.

[0042] In the present invention, "the catalyst is not substantially exposed to a hydrophilic environment" means that exposure to a hydrophilic environment is permitted to the extent that the catalyst is protected from the hydrophilic environment. "Protection of the catalyst from a hydrophilic environment is permitted" means that the activity of the catalyst accommodated in the complex of the present invention is maintained for a longer period of time in the same environment as compared with the case where a free catalyst is exposed to an in vivo environment, and can be evaluated, for example, by metabolic turnover (TON). The extent of permitted exposure may vary depending on the type of catalyst used, the type of protein used in combination, etc.

[0043] In one embodiment of the invention, "the catalyst is not substantially exposed to a hydrophilic environment" means that the relative solvent accessible surface area (SASA) of the catalyst when accommodated in a hydrophobic spot of the protein is 5.0 or less, preferably 4.0 or less, more preferably 3.5 or less, more preferably 3.0 or less, more preferably 2.5 or less, more preferably 2.0 or less, more preferably 1.5 or less, more preferably 1.0 or less, more preferably 0.9 or less, more preferably 0.8 or less, more preferably 0.7 or less, more preferably 0.6 or less, more preferably 0.5 or less, more preferably 0.4 or less, more preferably 0.3 or less, more preferably 0.2 or less, or more preferably 0.1 or less.

[0044] In another embodiment of the present invention, "the catalyst is not substantially exposed to a hydrophilic environment" means that 50% or more, preferably 55% or more, more preferably 60% or more, more preferably 65% ​​or more, more preferably 70% or more, more preferably 75% or more, more preferably 80% or more, more preferably 85% or more, more preferably 90% or more, more preferably 95% or more, more preferably 96% or more, more preferably 97% or more, more preferably 98% or more, or more preferably 99% or more of the total surface area of ​​the catalyst is accommodated within the hydrophobic spots of the protein. Alternatively, "the catalyst is not substantially exposed to a hydrophilic environment" means that the exposed area of ​​the catalyst to the hydrophilic environment is 50% or less, preferably 45% or less, more preferably 40% or less, more preferably 35% or less, more preferably 30% or less, more preferably 25% or less, more preferably 20% or less, more preferably 15% or less, more preferably 10% or less, more preferably 5% or less, more preferably 4% or less, more preferably 3% or less, more preferably 2% or less, or more preferably 1% or less of the total surface area of ​​the catalyst.

[0045] The protein that can be used in the complex of the present invention is not limited as long as it has one or more hydrophobic spots that allow the accommodation of a catalyst, and natural or artificial proteins can be used. Artificial proteins include mutant proteins in which a mutation is artificially introduced into a part of a natural protein.

[0046] In one embodiment, the protein used in the complex of the invention is one for which a ligand is readily available that binds to or interacts with one of its hydrophobic spots, which may be preferred in terms of facilitating ligand-mediated catalytic complexation.

[0047] In a specific embodiment, the protein used in the complex of the present invention is a protein selected from human serum albumin (HSA), immunoglobulin G (IgG), immunoglobulin A (IgA), transferrin, antitrypsin, haptoglobin, and α1-acid glycoprotein. These proteins are proteins that can move freely in the blood, and therefore are considered to be suitable for drug delivery systems. In yet another specific embodiment, the protein used in the complex of the present invention is a protein selected from myoferlin, Trk receptors, estrogen receptors, and folate receptors. These proteins are known to be highly expressed in cancer cells, and therefore it is considered possible to produce a complex capable of directly killing cancer by coordinating a ligand and a metal to the protein.

[0048] The organic catalyst or metal catalyst that can be used in the complex of the present invention is not particularly limited and can be arbitrarily selected by those skilled in the art. In one embodiment, the organic catalyst or metal catalyst that can be used in the complex of the present invention has the activity of changing a given prodrug into an active form.

[0049] For example, organic catalysts that can be used in the complex of the present invention include, but are not limited to, proline derivatives, phase transfer catalysts based on quaternary ammonium salt derivatives, thiourea derivatives, N-heterocyclic carbene derivatives obtained from thiazolium salts or imidazolium salts, cyclic ketone derivatives, 4-dimethylaminopyridine derivatives, and secondary amines such as amino acids.

[0050] For example, examples of metal catalysts used in the composite of the present invention include, but are not limited to, boron catalysts, magnesium catalysts, aluminum catalysts, silicon catalysts, calcium catalysts, scandium catalysts, titanium catalysts, vanadium catalysts, chromium catalysts, manganese catalysts, iron catalysts, cobalt catalysts, nickel catalysts, copper catalysts, zinc catalysts, yttrium catalysts, zirconium catalysts, niobium catalysts, molybdenum catalysts, ruthenium catalysts, rhodium catalysts, palladium catalysts, silver catalysts, indium catalysts, tin catalysts, barium catalysts, hafnium catalysts, tungsten catalysts, rhenium catalysts, osmium catalysts, iridium catalysts, platinum catalysts, gold catalysts, and lanthanoid Lewis acid catalysts. Examples of the lanthanoid Lewis acid catalyst include, but are not limited to, yttrium catalysts, lanthanum catalysts, cerium catalysts, samarium catalysts, europium catalysts, gadolinium catalysts, terbium catalysts, thulium catalysts, and lutetium catalysts.

[0051] A method for accommodating a catalyst in a hydrophobic spot of a protein can include, for example, binding the catalyst to the hydrophobic spot via a ligand that interacts with or binds to the hydrophobic spot. In this case, a linker such as a peptide, a hydrocarbon chain, or PEG can be used as appropriate to link the ligand to the catalyst (e.g., a metal catalyst). The length of the linker used should be such that the catalyst is accommodated in the hydrophobic spot and is not exposed or is not substantially exposed to the hydrophilic environment. That is, if the linker used is too long for the size of the hydrophobic spot, the ligand that interacts with it, and the catalyst used, when the catalyst is bound to the hydrophobic spot via the linker and the ligand, the catalyst may not fit within the hydrophobic spot, and a part or all of the catalyst may be exposed to the hydrophilic environment from the hydrophobic spot, and sufficient protection against the hydrophilic environment may not be obtained.

[0052] Another method for accommodating a catalyst in a hydrophobic spot of a protein is, for example, to activate the side chain functional groups (thiol and amino groups, respectively) of cysteine ​​or lysine present in or near the hydrophobic pocket of the protein with maleimide or succinimide, and then covalently bond the catalyst to the activated side chain functional groups.

[0053] Another method for accommodating a catalyst in a hydrophobic spot of a protein is to introduce a mutation at a specific position of the amino acid sequence constituting the hydrophobic pocket to introduce a double bond or azide, and then perform metathesis or click reaction to covalently bond the catalyst (Young TS, Ahmad I, Brock A, Schultz PG., Expanding the genetic repertoire of the methylotrophic yeast Pichia pastoris., Biochemistry. 2009. 48(12): 2643-53.; Wang L, Schultz PG., Expanding the genetic code., Angew Chem Int Ed Engl. 2004. 44(1): 34-66.). In this case, a catalyst having a linker such as a peptide or PEG can be used as the catalyst (e.g., a metal catalyst).

[0054] In one embodiment, the complex of the present invention is modified to interact with a target site in vivo. This allows the complex of the present invention to be directed to a desired site in vivo and / or to target a desired site. In this context, "interacting with a target site in vivo" can mean accumulating or typically binding to a target site with significantly stronger directional preference compared to other sites in vivo. In the present invention, the target site can be a specific organ or organ system, or a specific cell tumor, etc.

[0055] An example of such a modification is glycosylation. For example, it is known that the use of asparagine-linked glycans (N-linked glycans) in protein modification changes the targeting of specific organs depending on the cluster and / or number of bonds of the glycans (Tanaka, K., et al., Angew. Chem. Int. Ed., 49, 8195-8200 (2010); Latypova, L., et al., Adv. Sci., 1600394 (2017); Ogura, A., et al., Chem. Commun., 54, 8693-8696 (2018); Taichi, M., et al., Adv. Sci., 1700147 (2017)). For example, it is known that glycans with sialic acid at the end rapidly reach the liver, and glycans with galactose at the end rapidly reach the intestinal tract. Therefore, by modifying the complex of the present invention with an appropriate glycan structure and number of glycans depending on the selected in vivo target site, a complex with enhanced specificity for the target site can be obtained.

[0056] In one embodiment, the sugar chain modification can be, for example, a plurality of sugar chains (e.g., 5 to 30 sugar chains) having sialic acid, galactosamine, galactose, or mannose at the non-reducing end, which interact with various types of cancer. In an alternative embodiment, the sugar chain modification can be a sugar chain having fucose. In this embodiment, the plurality of sugar chains to be modified may be of the same type or of multiple types, and the size of each sugar chain can range from 1 sugar to 25 sugars.

[0057] In another embodiment, the sugar chain modification can be a plurality of sugar chains (e.g., 5 to 30) having sialic acid, galactosamine, galactose, or mannose at the non-reducing end, which selectively migrate to a specific organ such as the liver, pancreas, intestinal tract, gallbladder, bladder, or brain. In this embodiment, the plurality of sugar chains to be modified may be of the same type or of multiple types, and the size of each sugar chain can range from 1 sugar to 25 sugars.

[0058] The modification site is typically the protein surface of the complex. Methods for glycosylation of specific sites on the protein surface are known to those skilled in the art, and any method may be used. In the present invention, glycosylation can be introduced to the protein surface by click reaction, for example, as described in International Publication No. 2008 / 096760, Japanese Patent No. 6327547, International Publication No. 2017 / 002918, etc.

[0059] In another embodiment, the complex of the present invention further comprises a portion that interacts with a target site in vivo. In this context, "interacts with a target site" can mean that the target site accumulates or typically binds with a significantly stronger preference than other sites. In the present invention, the target site can be a specific organ or organ system, or a specific cell tumor, etc.

[0060] In the present invention, the "moiety that interacts with a target site in the body" may be an antibody or a fragment thereof, a peptide ligand or a fragment thereof, DNA or RNA, or pNA (peptide nucleic acid) or a fragment thereof, etc. In this regard, the "moiety that interacts with a target site in the body" may be produced, for example, as a fusion protein with a protein used in the complex, or the protein used in the complex and the "moiety that interacts with a target site in the body" may be prepared separately and linked (e.g., covalently linked) by means known to those skilled in the art.

[0061] In a specific embodiment, the present invention relates to an artificial metalloenzyme (ArM), which is a complex between a protein and a metal catalyst. In a preferred embodiment, the ArM of the present invention is a complex between HSA and a metal catalyst, and the complex is characterized in that the metal catalyst is accommodated in a hydrophobic spot of HSA so that the metal catalyst is not exposed or is not substantially exposed to a hydrophilic environment.

[0062] In this embodiment, the metal catalyst used with HSA can be appropriately selected by those skilled in the art depending on, for example, the type of prodrug to be activated, etc. In one embodiment of the present invention, the metal catalyst used with HSA is ruthenium.

[0063] In this embodiment, the hydrophobic spot of HSA that accommodates the metal catalyst is not particularly limited, and one hydrophobic spot may accommodate the metal catalyst, or multiple hydrophobic spots may accommodate the metal catalyst.The hydrophobic spot of HSA may include albumin drug binding site I and albumin drug binding site II.In one embodiment, the complex of the present invention accommodates the metal catalyst in albumin drug binding site I of HSA.

[0064] In this embodiment, the metal catalyst can be accommodated in the hydrophobic spot of HSA by linking the metal catalyst with a ligand for HSA and binding the metal catalyst in the hydrophobic spot via the ligand. The ligand that can be used for this purpose can vary depending on the hydrophobic spot that accommodates the metal catalyst. For example, when a metal catalyst is accommodated in the albumin drug binding site I of HSA, the ligand may be selected from warfarin, azapropazone, acenocoumarol, phenylbutazone, salicylate, indomethacin, phenytoin, tolbutamide, chlorpropamide, iofenoxate, iodipamide, sulfadimethoxine, fenoproxomone, glibenclamide, sulfathiazole, tenoxicam, camptothecin, valsidendeazid, anderelatan, diadereal, anderelatan, diadereal, anderelatan, diaderealtan, prodan, bilirubin, eicosanoids, and carboxy-methyl-propyl-furanpropanoate (a uremic toxin), and coumarin. Alternatively, when a metal catalyst is accommodated in the albumin drug binding site II of HSA, the ligand can be selected from diazepam, ketoprofen, clofibrate, ibuprofen, iopanoate, azidodeoxythymidine, flufenamate, ethacrynate, naproxen, flurbiprofen, cycloprofen, benoxaprofen, flucloxacillin, chlorothiazide, pirprofen, propofol, isoflurane, dansylsarcosine, dansylglycine, alkylaminocoumarin acetate, hydroxyflavone, L-tryptophan, medium chain fatty acid anions (e.g., octanoate), L-thyroxine, chloride ion, iodoacetic acid, indoxyl sulfate, and hippuric acid (a uremic toxin). In one embodiment of the present invention, the hydrophobic spot of HSA is drug binding site I, and a coumarin derivative, such as 7-dimethylaminocoumarin, is used as a ligand to accommodate ruthenium at the site.

[0065] The metal catalyst and the ligand may be linked via a linker. A linker that can be used for this purpose is typically an alkyl chain having an amino group and a carboxy group at both ends, or a polyethylene glycol (PEG) chain. Specifically, an alkyl chain linker is, for example, -NH-(CH 2 ) x -CO- (wherein x is an integer and is not limited as long as it does not inhibit the intended linker function, but can be, for example, an integer of 1 to 15), -NH-(CH 2 CH 2 O) y -CH 2 -CO- (wherein y is an integer and is not limited as long as it does not inhibit the intended linker function, but can be, for example, an integer of 1 to 15), or -NH-(CH 2 CH 2 O) z -CH 2 CH 2 -CO- (wherein z is an integer and is not limited as long as it does not inhibit the intended linker function, but can be, for example, an integer of 1 to 15).

[0066] When a linker is used to connect the metal catalyst and the ligand, it should be noted that the length of the linker used is such that the metal catalyst is accommodated in the hydrophobic spot of HSA and is not exposed or substantially not exposed to a hydrophilic environment. For example, when ruthenium is accommodated in the albumin drug binding site I of HSA using coumarin or its derivatives (e.g., 7-dimethylaminocoumarin, 7-diethylaminocoumarin (DEAC)) as a ligand, "substantially not exposed to a hydrophilic environment" may mean that the exposed area of ​​ruthenium to the hydrophilic environment is 40% or less, preferably 35% or less of the entire surface area of ​​ruthenium. Alternatively, "substantially not exposed to a hydrophilic environment" may mean that the SASA of ruthenium when accommodated in the albumin drug binding site I of HSA is 3.0 or less, preferably 1.0 or less. An exemplary linker used in this case is -NH-(CH 2 CH 2 O)y -CH 2 -CO-, where y can be an integer from 1 to 6, preferably an integer from 1 to 3.

[0067] In one embodiment, the ArM of the present invention is a complex of HSA and a metal catalyst, and the surface of HSA is modified with sugar chain. The content of sugar chain modification can vary depending on the target in vivo. The modification position on the HSA surface is not particularly limited as long as sugar chain can be introduced, and an example thereof can be the lysine residue at position 30 on the HSA surface.

[0068] The complex of the present invention can activate a prodrug in vivo depending on the type of catalyst contained in the complex. Preferably, the complex of the present invention can accumulate at a specific site in vivo depending on the type of catalyst contained in the complex and can activate a prodrug site-selectively.

[0069] Thus, in another aspect, the present invention relates to a composition comprising the complex of the present invention.

[0070] In one embodiment, the composition of the present invention is a pharmaceutical composition used in combination with a prodrug that can be activated by the complex of the present invention.In this embodiment, the pharmaceutical composition of the present invention may be in the form of a single agent further comprising a pharma- ceutically acceptable carrier and, optionally, a prodrug that can be activated by the complex of the present invention.The prodrug that can be activated by the complex of the present invention that can be used in the present invention can include, for example, various anticancer drugs, and can be exemplified by, but not limited to, mitomycin C, doxorubicin, taxol, endoxifen, etc.

[0071] In another embodiment, the pharmaceutical composition of the present invention is in the form of a combination drug in which the complex of the present invention and the prodrug that can be activated by the complex are provided as separate drugs. In the combination drug of the present invention, the first drug containing the complex of the present invention and the second drug containing the prodrug that can be activated by the complex can be administered to a subject at the same time or at different times.

[0072] In another aspect, the composition of the present invention relates to a pharmaceutical composition comprising a prodrug that can be activated by the complex of the present invention and an optional pharma- ceutically acceptable carrier, which can be characterized by being used in combination with the complex of the present invention.

[0073] In one embodiment, the pharmaceutical composition of the present invention can be used to selectively tag specific cells in a living body. In the present invention, "tagging" refers to tagging a target cell with a non-toxic chemical that can destroy cell function (e.g., adhesion inhibitors) or induce an immunological response, which can be endogenous or administered externally. Such a chemical can be an in vivo or ex vivo chemical that is converted from an inactive form to an active form by any metal catalyst, or an in vivo or ex vivo chemical whose function is enhanced by any metal catalyst. Such a technique in therapeutic applications is called selective cell tagging (SeCT), and is expected to indirectly induce the death of target cells (e.g., cancer cells) without significantly damaging the surrounding tissues, in contrast to conventional chemotherapy that directly removes cancer cells using highly cytotoxic drugs. For example, in the examples of the present application, it is shown that the binding of cRGD-propargyl ester (cRGD-PE) to integrins expressed on the surface of cancer cells can be enhanced by the complex of the present invention, thereby inhibiting metastasis.

[0074] In another embodiment, the composition of the present invention can be used as a biosensor. Specifically, in the complex of the present invention, a metal catalyst, a linker (e.g., a coumarin derivative) that is fluorescent by itself and / or whose fluorescence is enhanced by binding to a protein such as albumin, and a quencher that can be released by a reaction between the metal catalyst and a substance to be detected are used, so that the complex or composition of the present invention can be designed as an appropriate biosensor depending on the type of substance to be detected. In a specific embodiment of the present invention, the composition of the present invention is used as a biosensor for detecting ethylene in a plant.

[0075] It should be noted that the terms used in this specification are used to describe particular embodiments and are not intended to limit the invention.

[0076] Furthermore, the term "comprise" as used in this specification intends that the described items (components, steps, elements, numbers, etc.) are present, unless the context clearly indicates otherwise, and does not exclude the presence of other items (components, steps, elements, numbers, etc.).

[0077] Unless otherwise defined, all terms used herein (including technical and scientific terms) have the same meaning as commonly understood by those skilled in the art to which the present invention belongs. Terms used herein should be interpreted as having a meaning consistent with the meaning in the present specification and related technical fields, and should not be interpreted in an idealized or overly formal sense, unless otherwise defined.

[0078] Although terms such as first, second, etc. may be used to describe various elements, it is understood that these elements should not be limited by these terms. These terms are used only to distinguish one element from another element, and for example, a first element can be described as a second element, and similarly, a first element can be described as a second element, without departing from the scope of the present invention.

[0079] The present invention will be described in more detail below with reference to examples. However, the present invention can be embodied in various forms and should not be construed as being limited to the examples set forth herein. EXAMPLES

[0080] [Example 1] Preparation of alb-Ru To design biocompatible artificial metalloenzymes (ArMs) that can prevent the exposure of metal catalysts to solvents (with binding pockets), we exploited the drug binding site I of albumin (hydrophobic binding pocket as a pseudo-active site). To achieve this goal, we immobilized metal catalysts on drug binding site I, which is known to bind (interact) with coumarin derivatives (e.g., warfarin) (Ghuman, J.; Zunszain, PA; Petitpas, I.; Bhattacharya, AA; Otagiri, M.; Curry, SJ Mol. Biol. 2005, 353, 38-52). Coumarin-Ru complexes Ru1-3 and 6 with different PEG linker lengths were used to immobilize the metal catalysts.

[0081] 1. Preparation of coumarin-Ru complexes 1-1. General Procedure B Coumarin-bound ruthenium complexes Ru1-3,6 can be synthesized according to the following reaction scheme. [ka]

[0082] Ruthenium complex III is prepared according to known techniques (Lo, C.; Ringenberg, MR; Gnandt, D.; Wilson, Y.; Ward, TRChemComm 2011, 47, 12065-12067; Kajetanowicz, A.; Chatterjee, A.; Reuter, R.; Ward, TRCatal. Lett. 2014, 144, 373-379; Zhao, J.; Kajetanowicz, A.; Ward, TRCorg. Biomol. Chem. 2015, 13, 5652-5655). Hydrochloric acid gas is bubbled into a solution of ruthenium complex III (80.0 mg, 0.106 mmol) in dichloromethane (3 mL) at 25 °C. Hydrochloric acid gas is prepared by adding concentrated sulfuric acid dropwise to ammonium chloride. After stirring for 45 min, dichloromethane (1 mL) is added to the reaction via syringe and stirred at the same temperature. After an additional 15 min, the reaction is concentrated under reduced pressure to give amine IV, which is used in the next reaction without purification.

[0083] In a separate flask, a solution of carboxylic acid IIa (1.1 equiv.) and coupling agent HCTU (1.3 equiv.) in dichloromethane (1 mL) is stirred at 25° C. for 30 min. To this reaction, amine IV (1 equiv.) in dichloromethane (1 mL) is added followed by N,N-diisopropylethylamine (10 equiv.) at the same temperature. After stirring for 6 h, the reaction is quenched by adding 1 M aqueous HCl. The product is extracted three times with dichloromethane and the combined organic extracts are washed with saturated aqueous sodium bicarbonate and brine, dried (sodium sulfate), and concentrated under reduced pressure. The concentrated residue is purified by silica gel flash column chromatography to give the coumarin-Ru complexes Ru1-3,6.

[0084] 1-2. Preparation of coumarin-Ru complex Ru1 According to general procedure B, the reaction mixture obtained from ruthenium complex III (80.1 mg, 0.106 mmol), carboxylic acid IIa (42.4 mg, 0.117 mmol), HCTU (57.6 mg, 0.139 mmol) and N,N-diisopropylethylamine (137 mg, 1.06 mmol) was purified by silica gel flash column chromatography (cyclohexane / EtOAc / CHCl 3 After purification with 100% methanol / MeOH (40 / 40 / 15 / 5), the desired coumarin-Ru complex Ru1 (37.7 mg, 35.6%) is obtained as a green solid. 1 H-NMR (400MHz, CDCl 3 ,δ)1.24-1.27(m,12H),2.37-2.51(br m,18H),3.47(q,4H,J=7.1Hz),3.53-3.71(m,6H),3.79(m,1H),3.93(d,1H,J=15.3Hz),3.99(d,1H,J=15.3Hz),4.05(dd,1H,J 1 =J 2 =10.0Hz), 4.33(dd,1H,J 1 =J 2 =10.0Hz),4.75-4.84(br m,1H),4.89(sept,1H,J=6.1Hz),6.50(d,1H,J=2.3Hz),6.66(dd,1H,J 1 =2.3Hz,J 2 =9.1Hz),6.78(d,1H,J=7.7Hz),6.85(dd,1H,J 1 =J 2 =7.7Hz), 6.91(dd,1H,J 1 =1.7Hz,J 2 =7.7Hz),7.02(s,overlapped,2H),7.04(s,1H),7.07(s,1H),7.42(d,1H,J=9.1Hz),7.48(ddd,1H,J 1 =1.7Hz,J 2 =J 3 =7.7Hz),8.67(s,1H),9.09(s,1H),16.50(s.1H); HRMS(ESI)m / z 964.3355(964.3359 calcd for C50 H 61 ClN 5 O 6 Ru, [M-Cl] + ). [ka]

[0085] 1-3. Preparation of coumarin-Ru complex Ru2 According to general procedure B, the reaction mixture obtained from ruthenium complex III (80.1 mg, 0.106 mmol), carboxylic acid IIb (47.4 mg, 0.117 mmol), HCTU (57.1 mg, 0.138 mmol) and N,N-diisopropylethylamine (137 mg, 1.06 mmol) was purified by silica gel flash column chromatography (cyclohexane / EtOAc / CHCl 3 After purification with 100% methanol / MeOH (40 / 40 / 15 / 5), the desired coumarin-Ru complex Ru2 (27.9 mg, 25.2%) was obtained as a green solid. 1 H-NMR (400MHz, CDCl 3 ,δ)1.22-1.26(m,12H),2.26-2.46(br m,18H),3.38-3.54(m,4H),3.61-3.70(m,10H),3.74-3.82(m,1H),3.97(s,2H),4.11(dd,1H,J 1 =J 2 =10.3Hz), 4.28(dd,1H,J 1 =J 2 =10.3Hz),4.66-4.75(br m,1H),4.88(sept,1H,J=6.1Hz),6.47(d,1H,J=2.3Hz),6.65(dd,1H,J 1 =2.3Hz,J 2 =9.0Hz),6.77(d,1H,J=7.6Hz),6.83(dd,1H,J 1 =J 2 =7.6Hz), 6.89(dd,1H,J 1 =1.9Hz,J 2=7.6Hz),6.98-7.01(br m,4H),7.43(d,1H,J=9.0Hz),7.47(ddd,1H,J 1 =1.9Hz,J 2 =J 3 =7.6Hz),8.67(s,1H),9.05(s,1H),16.47(s.1H); HRMS(ESI) m / z 1008.3613(1008.3622 calcd for C 52 H 65 ClN 5 O 7 Ru, [M-Cl] + ). [ka]

[0086] 1-4. Preparation of coumarin-Ru complex Ru3 According to general procedure B, the reaction mixture obtained from ruthenium complex III (28.8 mg, 38.1 μmol), carboxylic acid IIc (18.9 mg, 42.0 μmol), HCTU (21.3 mg, 51.5 μmol) and N,N-diisopropylethylamine (49.7 μg, 385 μmol) was purified by silica gel flash column chromatography (cyclohexane / EtOAc / CHCl 3 After purification with 100% methanol / MeOH (40 / 40 / 15 / 5), the desired coumarin-Ru complex Ru3 (12.0 mg, 28.9%) was obtained as a green solid. 1 H-NMR (400MHz, CDCl 3 ,δ)1.22-1.28(m,12H),2.34-2.44(br m,18H),3.46(q,4H,J=7.2Hz),3.55-3.70(m,14H),3.71-3.80(m,1H),3.95(s,2H),4.04(dd,1H,J 1 =J 2 =10.7Hz), 4.27(dd,1H,J 1 =J 2=10.7Hz),4.57-4.65(m,1H),4.89(sept,1H,J=6.2Hz),6.47(d,1H,J=2.3Hz),6.65(dd,1H,J 1 =2.3Hz,J 2 =8.8Hz),6.79(d,1H,J=7.7Hz),6.84(dd,1H,J 1 =J 2 =7.6Hz), 6.89(dd,1H,J 1 =1.9Hz,J 2 =7.6Hz),7.01-7.05(br m,4H),7.42(d,1H,J=8.8Hz),7.47(ddd,1H,J 1 =1.9Hz,J 2 =J 3 =7.6Hz),8.67(s,1H),8.98(s,1H),16.47(s.1H); HRMS(ESI) m / z 1088.3661(1088.3648 calcd for C 54 H 70 Cl 2 N 5 O 8 Ru, [M+H] + ). [ka]

[0087] 1-5. Preparation of coumarin-Ru complex Ru6 According to general procedure B, ruthenium complex III (80.4 mg, 0.106 mmol), carboxylic acid IId (69.9 mg, 0.117 mmol), HCTU (57.5 mg, 0.139 mmol) and N,N-diisopropylethylamine (137 mg, 1.06 mmol) were purified by silica gel flash column chromatography (cyclohexane / EtOAc / CHCl 3 After purification with 100% methanol / MeOH (20 / 20 / 55 / 5), the desired coumarin-Ru complex Ru6 (34.4 mg, 26.3%) was obtained as a green solid. 1 H-NMR (400MHz, CDCl 3,δ)1.21-1.30(m,12H),2.37-2.45(br m,18H),3.45(q,4H,J=7.3Hz),3.56-3.68(m,31H),3.99(dd,1H,J 1 =J 2 =10.5Hz), 4.25(dd,1H,J 1 =J 2 =10.5Hz),4.53-4.62(br m,1H),4.91(sept,1H,J=6.1Hz),6.49(d,1H,J=2.3Hz),6.64(dd,1H,J 1 =2.3Hz,J 2 =8.8Hz),6.80(d,1H,J=7.6Hz),6.86(dd,1H,J=7.6Hz),6.90(dd,1H,J 1 =1.9Hz,J 2 =7.6Hz),7.03-7.07(br m,4H),7.42(d,1H,J=8.8Hz),7.48(ddd,1H,J 1 =1.9Hz,J 2 =J 3 =7.6Hz),8.68(s,1H),9.00(s,1H),16.47(s.1H); HRMS(ESI) m / z 1234.4603(1234.4593 calcd for C 61 H 84 Cl 2 N 5 O 11 Ru, [M+H] + ). [ka]

[0088] 2. Preparation of alb-Ru The alb-Ru complex was prepared by reacting the ruthenium catalysts Ru1-3 and 6 with human serum albumin (HAS) to form the alb-Ru complex. The composition of the reaction solution included 30 μM human serum albumin (hereinafter referred to as HSA; 50 nmol, 167 μL of 300 μM stock solution (aqueous solution) was used) and various concentrations of catalysts (Ru1-3, 6). For example, 37 μM Ru1 (62 nmol, 167 μL of 370 μM stock solution (dioxane solution) was used) was used as the catalyst. The total reaction volume was 1670 μL with PBS buffer (pH 7.4) containing 10% dioxane. After initiating the reaction by adding HSA, the reaction mixture was gently mixed and incubated at 37° C. for 1 hour. The reaction solution was then washed with PBS buffer and concentrated using an Amicon® ultracentrifugal filter (30 kDa). The concentrated alb-Ru solution was then diluted with PBS buffer to obtain 1000 μL as a 50 μM stock solution.

[0089] The formation of the Alb-Ru complex was confirmed by a fluorescence assay that relies on the fact that coumarin-based molecules are sensitive to solvent polarity. The fluorescence intensities (measured values) obtained in a 1:1 ligand-albumin reaction using Ru1-3,6 are shown in Figure 1. Compared with the controls (ligand alone or HSA alone), significantly higher fluorescence levels were detected, which is considered to be an indication of alb-Ru complex formation.

[0090] To indirectly determine the binding site of Ru1-3,6, a solution of HSA was preincubated with 2 equivalents of either binding ligand (warfarin or ibuprofen) for 1 h at 37 °C, and then a saturation binding curve of Ru1-3,6 was generated using the mixture of albumin and the binding ligand (Figure 2).

[0091] The results in Figure 2 reveal that the binding of Ru1-3,6 is unaffected in the presence of ibuprofen but significantly decreased in the presence of warfarin, strongly suggesting that drug-binding site I of HSA is the primary binding site for these compounds.

[0092] [Example 2] Verification of the reactivity of alb-Ru Next, we investigated the ability of the alb-Ru complexes to catalyze the ring-closing metathesis (RCM) of olefins 1a-1d and enyne 1e (Figure 3). Since alb-Ru 1-3 and 6 have different PEG linker lengths, we also examined the effective size and compatibility of the hydrophobic binding pocket.

[0093] The reaction mixture essentially contained 1a-e as substrates and alb-Ru complexes (i.e., Ru1-3,6) in 1:9 dioxane:PBS buffer (pH 7.4). After 2 h of incubation at 37°C, the reaction was quenched with dodecanethiol and further diluted with methanol, and the samples were filtered and analyzed by HPLC to calculate the turnover (TON) of each product 2a-e. As a control, reactions using free-in-solution ruthenium catalyst, Ru1-3,6, were also carried out under similar conditions. [Table 1]

[0094] One of the first observations in this experiment was the correlation between increasing PEG linker length (between the coumarin anchor and the ruthenium catalyst) and decreasing activity. For example, turnover of the substrate 4,4-bis((benzoyloxy)methyl)-1,6-heptadiene 1d (entry 7) was highest in the presence of alb-Ru1 (19.7), dropped sharply in the presence of alb-Ru2 (2.8), and showed negligible levels in the presence of alb-Ru6 (0.5). Given that turnovers (TON) obtained using the free ruthenium catalyst, Ru1, in solution for all linker lengths employed generally remained in the range of 28–35 (entry 8), this observation suggests that the hydrophobic binding pocket cannot accommodate the coumarin anchor-catalyst complex with the long linker.

[0095] [Example 3] Verification of biocompatibility of alb-Ru After confirming that the alb-Ru complex exhibited activity in catalyzing ring-closing and enyne cross-metathesis, we next sought to demonstrate its biocompatibility by evaluating the effect of glutathione. For this study, compound 1d was selected as a model substrate.

[0096] One of the key experiments in this study was to examine the catalytic protection ability of alb-Ru1 against glutathione. As shown below, substrate 1d was reacted with 1 mol% alb-Ru1 together with various concentrations of GSH. Note that equivalent amounts of glutathione were added depending on the concentration of alb-Ru1. [ka]

[0097] As a result, no change in (calculated) TON was observed up to 20 mM GSH (1000 equivalents of GSH relative to alb-Ru). Addition of 100 mM and 200 mM GSH ultimately resulted in a TON reduction of 60% and 82%, respectively, compared to the control.

[0098] In the next study, we evaluated the duration of metal-catalyzed protection to determine the upper threshold of GSH protection capacity. Specifically, alb-Ru1 was preincubated with either GSH, dodecanethiol, or PBS buffer (as blank) for various times, after which substrate 1d was added to the reaction mixture, and TON values ​​were calculated after 1 h of reaction. Figure 4 shows the experiment performed at a physiologically relevant GSH concentration (200 μM, 10 equivalents relative to alb-Ru1).

[0099] TON values ​​measured after 6 h preincubation with GSH generally showed only a slight decrease compared to the blank (PBS buffer). In contrast, experiments with upper threshold GSH (20 mM, 1000 equivalents relative to alb-Ru1) showed a pronounced (much larger) effect on reactivity (Figure 5).

[0100] In this case, after 1 h preincubation with GSH, a decrease in activity of about 50% was observed, whereas after 4 h preincubation the activity was almost abolished.

[0101] To further evaluate the biocompatibility of the Alb-Ru complex, substrate 1d was incubated with 10 mol% of the alb-Ru1 complex at 37°C for 2 h. The formation yield of 2d was about 2% in 1:8:1 fetal bovine serum / DMEM medium / dioxane and about 1% in 1:8:1 normal rat serum / PBS buffer / dioxane. However, the low formation yield is likely due to trapping or degradation of the substrate by proteins normally present in serum, since the recovered starting material 1d was approximately 8% and 3%, respectively.

[0102] Regarding ArM activity (artificial metalloenzyme activity), the Michaelis-Menten kinetic parameters of substrates 1a-e were calculated with and without the addition of GSH (Figure 6).

[0103] As a result, the kinetic values ​​measured for ArM activity in 1a-1e, with or without GSH addition, showed only slight changes (within error). However, of particular importance was the observed catalytic efficiency (k cat / K M ) is the difference between the substrate 1e and the substrate 1e. 3 M -1 s -1 k cat / K M This value corresponds to the reactivity of the native enzyme (k cat / K M ~10 8 M -1 s -1 ), this result emphasizes that non-native metal ArMs may reach reactivity comparable to that of the native enzyme.

[0104] [Example 4] Mechanism of glutathione resistance To predict the degree of invasion and conformation in the hydrophobic binding pocket of drug binding site I of albumin, a molecular modeling study was performed using Autodock 4.2 (Morris, GM; Huey, R.; Lindstrom, W.; Sanner, MF; Belew, RK; Goodsell, DS; Olson, AJ) with the AutoDockTools GUI interface to dock compounds Ru1-3,6 to human serum albumin (PDB:1H9Z). The results support the underlying hypothesis that the binding pocket of drug binding site I of albumin is deep enough to accommodate the binding of coumarin-ruthenium catalysts (e.g., Ru1) with relatively short PEG linker lengths. However, as shown in Figure 7, gradually increasing the PEG linker length (e.g., Ru6) pushes the ruthenium moiety outside the binding pocket, increasing its exposure to biomolecules in solution.

[0105] This theory was further supported by the fact that calculations of the relative solvent accessible surface area (SASA) of the ruthenium atoms of the docking ligand also showed increasing correlation with longer PEG linkers, with a zero value in Figure 7 indicating atoms that are not exposed to the solvent.

[0106] [Example 5] Targeting of artificial metalloenzymes Another aspect that needs to be considered to advance the development of therapeutic ArMs is the need for targeting methodologies to facilitate localization to specific organs / cells in the body.

[0107] If successful, this could enable applications in prodrug therapy, which would be particularly beneficial for the development of drug candidates that carry a risk of side effects, such as anti-cancer therapies based on cytotoxic molecules.

[0108] The glycocalyx that envelopes the surface of different eukaryotic cells varies in complexity, and glycoalbumins that bind specific complex N-glycan populations have been found to be able to differentially recognize and bind to different cancer cells. In a key study aimed at testing the ability of these glycoalbumins to act as in vivo carriers, for propargyl ester-based protein labeling, glycoalbumins containing gold catalysts were localized to specific organs in living mice by their N-glycan structures and showed in vivo catalytic activity (Tsubokura, K.; Vong, K. K. H.; Pradipta, A. R.; Ogura, A.; Urano, S.; Tahara, T.; Nozaki, S.; Onoe, H.; Nakao, Y.; Sibgatullina, R.; Kurbangalieva, A.; Watanabe, Y.; Tanaka, K. Angew. Chem. Int. Ed. Engl. 2017, 56, 3579-3584.).

[0109] To explore the applicability to cancer, we selected a homogeneous population of N-glycans with sialic acid α(2,3) linkages as a targeting group. This selection was based on previous studies showing that glycoalbumin with sialic acid α(2,3) linkages (2,3-Sia) can preferentially accumulate in SW620 human colon adenocarcinoma cells and also showed moderate binding to A549 human alveolar basal epithelial adenocarcinoma cells and HeLa human cervical carcinoma cells (Ogura, A.; Urano, S.; Tahara, T.; Nozaki, S.; Sibgatullina, R.; Vong, K.; Suzuki, T.; Dohmae, N.; Kurbangalieva, A.; Watanabe, Y.; Tanaka, K. ChemComm 2018, 54, 8693-8696.). This effect is likely mediated by overexpression of galectin-8, a known receptor for α(2,3)-linked sialic acid. (Lahm, H.; Andre, S.; Hoeflich, A.; Fischer, JR; Sordat, B.; Kaltner, H.; Wolf, E.; Gabius, H.-JJCancer Res. Clin. Oncol. 2001, 127, 375-386; Carlsson, S.; Oberg, CT; Carlsson, MC; Sundin, A.; Nilsson, UJ; Smith, D.; Cummings, RD; Almkvist, J.; Karlsson, A.; Leffler, H.Glycobiology 2007, 17, 663-676.)

[0110] First, we prepared glycosylated ArM (GArM)-Ru1(2,3-Sia) with immobilized ruthenium catalyst Ru1, and then evaluated its targeting ability to SW620 human colon adenocarcinoma cells in a binding assay. To evaluate the specific binding of GArM-Ru1(2,3-Sia) to cancer cells, cancer cells were plated at 10 4The cells were seeded at a density of 100 cells / well and cultured overnight. The medium was then removed, and [1]GArM-Ru1(2,3-Sia), [2]alb-Ru, [3]GA(2,3-Sia), or [4]Ru1 was added to a final concentration of 10 μM. The cells were incubated at 37°C for 3 hours, after which the medium was removed, washed with PBS buffer (3 times), and fixed on the plate using formaldehyde reagent. Cell observation was performed using a Keyence BZ-X710 All-in-one Fluorescence Microscope (registered trademark), and fluorescent and bright field images were recorded. ET-EBFP2 / Coumarin / Attenuated DAPI Filter Set Cat#49021 (Chroma Technology Corp., Vermont, USA) was used to detect coumarin-derived fluorescence. Images were taken at 20x magnification and analyzed using BZ-X Analyzer (Keyence) software.

[0111] The results are shown in Figure 8. Cellular imaging using the fluorescence emission of coumarin bound to HSA revealed stronger fluorescence accumulation in SW620 human colon adenocarcinoma cells incubated with GArM-Ru1(2,3-Sia) compared to the control.

[0112] As an additional test, we also performed similar experiments using HeLa human cervical carcinoma cells and A549 human alveolar basal epithelial adenocarcinoma cells. Consistent with previous reports, we observed that the accumulation of GArM-Ru1(2,3-Sia) in SW620 human colon adenocarcinoma cells was higher than that in HeLa human cervical carcinoma cells and A549 human alveolar basal epithelial adenocarcinoma cells (Figure 9).

[0113] [Example 6] Prodrug therapy We next investigated the applicability of the GArM-Ru complex to targeted anticancer therapy.Umbelliprenin (2h) was selected as an initial drug candidate that can be activated by ring-closing metathesis. [ka]

[0114] Umbelliprenin, a natural product extracted from the Ferula plant, has been shown to have cytotoxic activity against various cancer cell lines (Shakeri, A.; Iranshahy, M.; Iranshahi, MJAsian. Nat. Prod. Res. 2014, 16, 884-889; Rashidi, M.; Khalilnezhad, A.; Amani, D.; Jamshidi, H.; Muhammadnejad, A.; Bazi, A.; Ziai, SAJ Cell. Physiol. 2018, 233, 8908-8918; Jun, M.; Bacay, AF; Moyer, J.; Webb, A.; Carrico-Moniz, D. Bioorganic Med. Chem. Lett. 2014, 24, 4654-4658.). Its mechanism of cytotoxicity has been shown to arrest cells in the G1 phase and induce apoptosis by activating caspases-8 and -9 and downregulating Bcl-2 and Mcl-1 (Barthomeuf, C.; Lim, S.; Iranshahi, M.; Chollet, P. Phytomedicine 2008,15,103-111; Gholami, O.; Jeddi-Tehrani, M.; Iranshahi, M.; Zarnani, AH; Ziai, SAIran J.Pharm.Res. 2013,12,371-376; Gholami, O.; Jeddi-Tehrani, M.; Iranshahi, M.; Zarnani, AH; Ziai, SAIran J.Pharm.Res. 2014,13,1387-1392.). We theorized that due to its extremely high hydrophobicity (mainly conferred by the farnesyl moiety), the prodrug of umbelliprenin (1h) would be an ideal substrate for albumin-based ArMs. [ka]

[0115] To test this, kinetic experiments were performed using both the simplified coumarin derivative 1g and the umbelliprenin prodrug 1h (Figure 10).

[0116] Although coumarin precursors are generally known to have poor RCM reactivity under aqueous conditions, the negligible reactivity (k cat / K M The very low binding affinity (K < 1) of precursor 1g to albumin was unexpected. D 129 μM) as shown by the results of binding experiments. On the other hand, the hydrophobic prodrug 1h showed significantly higher activity (at least 1500-fold higher k compared to 1g). cat / K M ) is likely due to the long alkyl chain moiety of 1h, which facilitates entry into the hydrophobic binding pocket.

[0117] We next performed a series of experiments to evaluate the in cellulo activity of the GArM-based anticancer approach. Cytotoxicity tests were performed using the prodrug 1h at specific concentrations (32 μM in SW620 human colon adenocarcinoma cells; 64 μM in HeLa human cervical carcinoma cells and A549 human alveolar basal epithelial adenocarcinoma cells) and varying the amount of GArM-Ru1 added.

[0118] The cell viability was measured using Promega's CellTiter 96 (registered trademark) Aqueous One Solution Cell Proliferation Assay (MTS). The cultured cells were plated in a Falcon (registered trademark) 96-well microplate at approximately 10 3 Cells were seeded at a density of 1000 cells / well and cultured overnight. The medium was then removed and various concentrations of compounds were added. DMSO was used to dissolve the compounds, and the DMSO concentration was 1% when added to the cells. After 96 hours of incubation, the cell culture medium was replaced with 85 μL of fresh medium. Then, 15 μL of MTS reagent was added, and after 2.5 hours of incubation at 37°C, the absorbance was measured at 490 nm. The absorbance of the cells to which 1% DMSO was added as a control was taken as 100%, and the cell viability was calculated. To illustrate the effect of glycan targeting, experiments were performed under similar conditions using alb-Ru1 without glycans as a control. These results showed that in all three cancer cell lines, the mixture of prodrug 1h and GArM-Ru1 significantly reduced cell proliferation (<5%), an effect that exceeded that of the corresponding concentrations of prodrug 1h and GArM-Ru1 (Figure 11). Another important observation was that the cytotoxic activity of the mixture of prodrug 1h and alb-Ru1 was much less effective. This suggests that glycan targeting is important for the localization of metal catalysts on the cell surface and inside the cells.

[0119] [Example 7] Synthesis of artificial metalloenzyme (ArM) for detecting ethylene (ArM ethylene probe; AEP)

[0120] FIG. 12 depicts the synthesis scheme of the ArM ethylene probe (AEP). The fluorescence emitted by 7-diethylaminocoumarin (DEAC) itself is highly sensitive to the polarity of the surrounding solvent, and the quantum yield of DEAC-Ru increases by about 20 times when the environment is changed from a polar environment (10% dioxane / water) to a non-polar environment (60% dioxane / water). Therefore, in this synthesis, AEP was synthesized based on the reaction of alb-Ru with an olefin-containing DABCYL quencher.

[0121] 7-1. Preparation of AEP alb-Ru was prepared by mixing a 30 μM HSA solution (50 nmol, 167 μL from a 300 μM aqueous solution) with a 37 μM DEAC-Ru solution (62 nmol, 167 μL from a 370 μM dioxane solution). The reaction solution was a PBS buffer solution at pH 7.4 containing 10% dioxane, with a total volume of 1670 μL. After initiating the reaction by adding HSA, the reaction solution was gently stirred and incubated at 37 degrees for 1 hour. The reaction solution was then concentrated using an Amicon Ultra centrifugal filter (30 kDa) and washed three times with PBS buffer solution. The concentrated alb-Ru solution was diluted to 50 μL with water to obtain a 1 mM stock solution. To prepare the AEP solution, a mixture of 100 μM alb-Ru solution (50 nmol, 50 μL from a 1 μM aqueous solution) and 500 μM DABCYL quencher solution (250 nmol, 450 μL from a 555 μM DMSO:water = 1:8 solution) was made. The reaction solution was gently stirred and incubated at 37 degrees for 5 minutes. The reaction solution was then concentrated using an Amicon Ultra centrifugal filter (30 kDa) and washed three times with PBS buffer solution. The concentrated AEP solution was diluted to 500 μL with water to obtain a 100 μM stock solution.

[0122] The fluorescence intensity of the protein complex (alb-Ru, AEP) was measured using a JASCO FP-6500 Spectrofluorometer with a JASCO FMP-963 microplate reader. To prepare the samples, both alb-Ru and AEP were dissolved in water at a concentration of 10 μM. The samples were then aliquoted (100 μL) into a 96-well microplate and analyzed at λ EX =420nm / λ EM = 463 nm. All measurements were performed in triplicate.

[0123] Circular dichroism (CD) analysis was also performed to distinguish the major structural changes of the protein complexes (alb-Ru, AEP) used in this study. CD spectra were measured using a J-1500 Circular Dichroism Spectrometer (JASCO) with a 0.1 cm cell. A 10% aqueous solution of dioxane was used as a blank, which was automatically subtracted from the sample during scanning. Data were recorded from 200-250 nm at a scan speed of 100 nm / min. The concentration of each protein complex was kept at 2.3 μM.

[0124] [result] The RuQ complex (DEAC-Ru-DABCYL complex) present in the binding pocket of albumin has a significantly low fluorescence intensity due to the quencher, which is evident from the comparison of the fluorescence intensities of alb-Ru and the AEP probe in Figure 13. Furthermore, the complete overlap of their circular dichroism (CD) spectra confirmed that no significant structural denaturation of the protein was observed (Figure 14).

[0125] 7-2. Detection of ethylene by AEP The mechanism of ethylene detection by AEP is that ethylene reacts with the ruthenium catalyst in AEP, replacing it with the DABCYL quencher and activating it into a fluorescent signal. Therefore, in this example, AEP was used to detect ethylene in fruits and plants.

[0126] [Kiwi fruit imaging] Unripe and ripe kiwifruit were purchased from a grocery store. Kiwifruit pieces were prepared by cutting the fruit into pieces with a kitchen knife, approximately 2.0 cm x 4.5 cm in size, to obtain pieces containing the outer pericarp, locule, and columella. To follow ethylene production, 170 μL of AEP (400 μM solution) was poured into the center of a 10 cm petri dish. The sample was then applied on top of the AEP solution. The sample was incubated at room temperature and imaging was performed at specific times (1 and 24 hours). For imaging, a Keyence BZ-X710 All-in-one Fluorescence Microscope® equipped with an ET-EBFP2 / Coumarin / Attenuated DAPI Filter Set Cat#49021 (Chroma Technology Corp.) was used. Brightfield images (color) were obtained with an exposure setting of 1 / 25th second, and fluorescence images were obtained with an exposure setting of 1 / 3.5th second. Multiple imaging images were acquired at 4x magnification, and image merging and analysis were performed using BZ-X Analyzer software (Keyence).

[0127] [Imaging Arabidopsis thaliana] Arabidopsis thaliana was 85 μmol m -2 s -1 The plants were grown under a light intensity of 1000 Hz and 1400 Hz. A photoperiod of 10 h light and 14 h dark was applied. To track ethylene production, leaves were harvested from 4-6 week old plants. The transparent epidermal skin was then peeled off from the leaves using forceps and placed in a 96-well clear bottom plate. After adding water (100 μL), the samples were incubated at room temperature for 12 h to exclude the effect of wound stress. Depending on the experimental conditions, 1 mM ACC solution (2 μL of 55 mM in water), 4.8 μM flg22 or elf18 solutions (5 μM and 100 μM in water), OD 600 = 0.02 (OD of 2 μL of Pseudomonas bacteria solution) 600Various solutions were added as required, including a standard solution with a pH of 1.0 (=1.0). In experiments involving ACC and Pseudomonas bacteria, a 12-hour incubation at room temperature was applied. Meanwhile, in experiments involving PAMPs, a 6-hour incubation at room temperature was performed. These solutions were then completely removed from the epidermal peel samples, and a 100 μM AEP solution (50 μL from a stock solution) was added. After 30 minutes, the solutions were completely removed and washed with water, after which imaging was performed using a Keyence BZ-X710 All-in-one Fluorescence Microscope® equipped with an ET-EBFP2 / Coumarin / Attenuated DAPI Filter Set Cat#49021 (Chroma Technology Corp.). Imaging images were obtained at 20x and 40x magnification, with exposure settings of 1 / 400th of a second for brightfield images (monochrome) and 1 / 30th of a second for fluorescent images. Multiple imaging images were obtained at 4x magnification, and analysis was performed using the BZ-X Analyzer software (Keyence).

[0128] [result] Spatial detection of ethylene in fruits. In general, climacteric fruits produce more autocatalytic ethylene (system 2) during ripening. This is also the case in response to external stimuli such as wound stress and pathogen infection. In this study, we first investigated endogenous ethylene using an AEP probe. It has been reported that ethylene production increases in the outer pericarp of kiwifruit during ripening via upregulation of ACS isogenes. In our imaging experiments of kiwifruit using AEP, we focused on observing the changes in ethylene production expressed in various organelles (outer pericarp, ovary locule, and colum) at different developmental stages (unripened and ripened). As summarized in Figure 15, a significant increase in fluorescence intensity was observed in the outer pericarp as the fruit progressed from unripened to ripened. On the other hand, the changes in fluorescence intensity in the ovary locule and colum of kiwifruit were not observed to a great extent. These results revealed that the use of AEP is a promising tool to detect fruit ripening and ethylene expression during the ripening period.

[0129] Ethylene detection in plants To investigate the effect of AEP detection in plants, we chose the small flowering plant Arabidopsis thaliana (Brassicaceae) as a model plant. To demonstrate conclusively that AEP can detect ethylene production, we performed comparative experiments using small molecules known to regulate ethylene production and various plant mutants involved in ethylene production.

[0130] In this study, we used Arabidopsis Col-0 ecotype as a wild-type model plant. In addition, we also used a wide variety of plant mutants, including acs1 / 2 / 6 / 4 / 5 / 9 / 7 / 11 and eto1-1. The acs1 / 2 / 6 / 4 / 5 / 9 / 7 / 11 mutant is a knockout mutant of eight ACS genes, and the amount of ethylene does not increase even when pathogens invade. This is because ACS plays a key role in the ethylene biosynthesis pathway. Another mutant, eto1-1, was used, which overproduces ethylene. Through expression of ethylene-overexpression protein 1 (ETO1), proteasome-dependent degradation is suppressed and ACS activity is up-regulated. This is based on the interaction between the C-terminus of type II ACS and ETO1.

[0131] Imaging images of Col-0 incubated at room temperature with or without AEP are shown in Figure 16. As quantified in Figure 17, a significant increase in fluorescence intensity was observed, thereby confirming the applicability of AEP for ethylene detection in the Arabidopsis epidermal bark. As a positive control, Col-0 exogenously stimulated with ACC (ethylene production) was compared. As expected, it showed a higher increase in fluorescence intensity compared to wild-type Col-0.

[0132] [Example 8] Selective tagging of cancer cells with cRGD using glycosylated ArM In many studies, the cyclic Arg-Gly-Asp (cRGD) pentapeptide was synthesized in αvβ cells overexpressed on the surface of cancer cells.3 and αvβ 5It has been reported that it is effective in inhibiting integrins and preventing adhesion to the extracellular matrix (JS Desgrosellier, DACheresh, Integrins in cancer: Biological implications and therapeutic opportunities. Nat. Rev. Cancer 10, 9-22 (2010).; M. Pfaff, K. Tangemann, B. Muller, M. Gurrath, G. Muller, H. Kessler, R. Timpl, J. Engel, Selective recognition of cyclic RGD peptides of NMR defined conformation by αIIbβ3,αvβ3,and α5β1 integrins. J. Biol. Chem. 269, 20233-20238 (1994).; and M. Aumailley, M. Gurrath, G. Muller, J. Calvete, R. Timpl, H. Kessler, Arg-Gly-655 Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of 656 cell adhesion to vitronectin and laminin fragment P1. FEBS Lett.291,50-54 657(1991).).In addition, RGD-based antagonists against integrins expressed on vascular endothelial cells have been shown to promote tumor regression by inhibiting angiogenesis (PC Brooks, AMP Montgomery, M. Rosenfeld, RA Reisfeld, T. Hu, G. Klier, DACheresh, Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79, 1157-1164 (1994).; and DG Stupack, DACheresh, Integrins and angiogenesis. Curr. Top. Dev. Biol. 64, 207-238 (2004).). In this example, we investigated whether glycosylated ArM (GArM) could be used for selective cell tagging (SeCT) therapy to disrupt cancer cell adhesion at the single cell level, mimicking the seeding process of micrometastasis. Specifically, we investigated whether selective accumulation of HeLa-targeting GArM complexes in cancer cells followed by selective tagging of surface proteins with cRGD could be achieved.

[0133] 8-1. Preparation of cRGD-PE The scheme used to prepare cRGD-PE was as follows:

[0134] [ka]

[0135] (Preparation of Compound I) The product was synthesized by standard solid-phase peptide synthesis techniques. After cleavage from the solid support, the mixture was directly purified by reversed-phase HPLC using a linear gradient of 20-80% acetonitrile in water (0.1% TFA) over 40 min. Yield: 2.92 g, 89%, ESI-HRMS m / z calcd for C 53 H 83 N 9 O 14S([M+H] + )1102.5853,found 1102.5859.

[0136] (Preparation of Compound II) Compound I (90.1 mg, 0.0833 mmol) and EDC (17.6 mg, 0.0916 mmol) were dissolved in methylene chloride (0.5 mL). The solution was then stirred at room temperature for 3.5 h. For work-up, methylene chloride was added and the organic layer was washed with water / saturated brine, dried over magnesium sulfate, and concentrated under reduced pressure. Mass spectrometry of the resulting residue confirmed the formation of the target product. ESI-HRMS m / z calcd for C 53 H 81 N 9 O 13 S ([M+H] + )1084.5747,found 1084.5744. The resulting protected peptide was subsequently deprotected by dissolving it in a solution of TFA / methylene chloride (1:1) for 2 h. The mixture was concentrated under reduced pressure and directly purified by reversed-phase HPLC using a linear gradient of 20-80% acetonitrile in water (0.1% TFA) over 40 min. Yield: 54.5 mg, 77% (2-step yield). ESI-HRMS m / z calcd for C 27 H 41 N 9 O 8 ([M+H] + )620.3151,found 620.3169.

[0137] (Preparation of Compound III) A solution of adipic acid (1.0 g, 6.84 mmol) in DMF (20 mL) was stirred, and N-hydroxysuccinimide (3.0 g, 27.4 mmol) and EDC (5.14 g, 27.4 mmol) were added. After stirring the solution at room temperature for 24 hours, the reaction mixture was concentrated under reduced pressure, and the crude product was dissolved in 200 mL of acetone and 250 mL of 1 M aqueous hydrochloric acid was added dropwise. After 2 hours, the white precipitate was collected by filtration and washed with water and acetone to obtain the desired product (1.75 g, 77%). 1 H NMR (500 MHz, CDCl 3,25℃) δ2.84(s,4H),2.83(s,4H),2.67(t,J=3.5Hz,4H),1.89(t,J=3.5Hz,4H); 13 C NMR (125 MHz, CDCl 3 ,25℃) 169.4,168.4,30.7,25.9,23.9.ESI-HRMS m / z calcd for C 14 H 17 N 2 O 8 ([M+H] + )341.0979,found 341.0973.

[0138] Preparation of Compound IV A solution of compound II (28.8 mg, 0.034 mmol) and compound III (23.2 mg, 0.068 mmol) in DMF (680 mL) was stirred and DIEA (16.8 μL, 0.10 mmol) was added. After stirring the solution at room temperature for 24 h, the mixture was directly purified by reversed-phase HPLC under the same conditions used to prepare compound I, yielding the desired compound (14.0 mg, 43%). 1 H NMR (500MHz, CD 3 OD,25℃) δ7.00(d,J=6.5Hz,2H),6.68(d,J=6.5Hz,2H),4.74(t,J=7.0Hz,1H),4.41(q,J=7.0Hz,1H),4.26-4.30(m,2H),3 .91-3.86(m,1H),3.22-3.18(m,1H),3.14-3.10(m,1H),3.09(t,J=6.5Hz,2H),2.91-2.85(m,2H),2.84-2.78(m,5 H),2.59(t,J=9.5Hz,2H),2.64-2.60(m,1H),2.58(dd,J=16.5,9.0Hz,1H),2.19(t,J=7.0Hz,2H),2.22(t,J=7.0 ESI-HRMS m / z calcd for C 37 H 53 N 10 O 13 ([M+H]+ )845.3788,found 845.3769.

[0139] (Preparation of cRGD-PE) A solution of compound IV (4.2 mg, 3.9 μmol) and compound V (1.1 mg, 7.8 μmol) in DMF (200 μL) was stirred, and DIEA (3.3 μL, 19.6 μmol) was added. After stirring the solution at room temperature for 24 hours, the mixture was directly purified by reverse-phase HPLC under the same conditions used to prepare compound I, yielding cRGD-PE (3.2 mg, 85%). 1 H NMR (500MHz, CD 3 OD,25℃) 7.02(d,J=7.0Hz,2H),6.71(d,J=7.0Hz,2H),4.76(t,J=7.5Hz,1H),4.75(s,2H),4.44(t,J=7.5Hz,1H),4.29-4.20(m, 2H),3.98(s,2H),3.91(dd,J=9.5,3.0Hz,1H),3.25-3.20(m,1H),3.18-3.11(m,1H),3.11(t,J=7.0Hz,2H),2.96(s,1H) ,2.88(d,J=8.0Hz,2H),2.85(dd,J=16.5,8.0Hz,1H),2.58(dd,J=16.5,8.0Hz,1H),2.29(t,J=7.0Hz,2H),2.22(t,J=7 ESI-HRMS m / z calcd for C 38 H 55 N 10 O 12 ([M+H] + )843.3995,found 843.4006.

[0140] 8-2. Preparation of GArM complex Using a previously reported method, we investigated the glycoconjugation of α(2,3)-sialic acid-terminated glycan-aldehyde probe (R.Sibgatullina, K.Fujiki, T.Murase, T.Yamamoto, T.Shimoda, A.Kurbangalieva, K.Tanaka, Highly reactive “RIKEN click” probe for glycoconjugation on lysines. Tetrahedron Lett.58,1929-1933 (2017).) and gold catalyst bound to coumarin (K.Tsubokura, KKVong, ARPradipta, A.Ogura, S.Urano, T.Tahara, S.Nozaki, H.Onoe, Y.Nakao, R.Sibgatullina, A.Kurbangalieva, Y.Watanabe, K.Tanaka, In vivo gold complex catalysis within live mice. Angew. Chem. Int. Ed. 56, 3579-3584 (2017).) was synthesized.

[0141] A DMSO solution of a terminal α(2,3)-sialic acid glycan-aldehyde probe (1 μmol, 15 equivalents, 260 μL from a 3.8 mM stock solution) was added to a solution of human serum albumin (5.3 mL of aqueous solution, 66.7 nmol) under air. The solution was gently stirred and incubated overnight at 37°C. The solution was then concentrated using an Amicon Ultra centrifugal filter (30 kDa) and washed with water. Insoluble by-products were removed using a Durapore membrane (Durapore PVDF 0.45 μm (registered trademark)), and the solution was diluted with water to obtain a 1.0 mM stock solution of glycated albumin. The number of bound glycans was confirmed using MALDI-TOF-MS (positive mode), which detected the molecular weight (85.8 kDa) of glycated albumin to which 6.2 glycan molecules were bound per one molecule of albumin. In the next step of the protocol, a solution of coumarin-gold conjugate (66.7 nmol) in DMSO (6.1 μL) was added to a solution of glycosylated albumin (66.7 nmol) in PBS buffer (60.6 μL, pH 7.4). The solution was gently stirred and incubated at 37°C for 1 h. The solution was then concentrated using an Amicon Ultra centrifugal filter (30 kDa) and washed with PBS buffer to obtain the desired GArM conjugate.

[0142] (cell) HeLa cancer cells express RGD-specific integrin (α 5 β 1 , αvβ 3 , αvβ 5 In this study, HeLa cells were selected as a model because they are known to overexpress the chromosome 1 (K1) gene. HeLa cells were provided by the Cell Culture Development Laboratory of the Institute of Physical and Chemical Research.

[0143] HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS) and 1% penicillin-streptomycin. The HeLa-Luc cell line was generated by stable transfection of HeLa cells with firefly luciferase and puromycin acetyltransferase cultured in DMEM containing 10% FBS and 0.01% puromycin. The HeLa-V cell line was generated by stable transfection of HeLa cells with firefly luciferase and Venus (V) cultured in DMEM containing 10% FBS, 1% penicillin-streptomycin, and 0.8% geneticin. All cell lines were grown in a 37°C incubator containing 5% carbon dioxide. Mouse macrophages were obtained from the peritoneal cavity of BALB / c-nu / nu mice administered 0.9% saline (6 mL) as previously described (A. Ray, BN Dittel, Isolation of mouse peritoneal cavity cells. JoVE, e1488 723 (2010).).

[0144] 8-3. Verification of selectivity of GArM to HeLa cells To determine whether GArM could be targeted more selectively to HeLa cells, we performed a series of flow cytometry studies. The fluorescence intensity of coumarin derivatives is known to increase upon binding to albumin; Ex =405nm / λ Em The fluorescence intensity measured at = 470 nm is an indication of whether the coumarin-linked GArM complexes have bound to the cells.

[0145] Flow cytometry and cell sorting were performed by standard techniques using a Sony SH800 Cell Sorter (Sony Corporation). The flow cytometer was equipped with 405, 488, 561, and 638 nm lasers, and λ Ex =405nm / λ Em = 470 nm, λ for Venus (V) detection Ex =515nm / λEm Gating at excitation / emission wavelengths of =528 nm, respectively, was used and the results were analyzed using Sony SH800 software.

[0146] First, in a cell culture system, a clear difference in peaks was observed in flow cytometry between HeLa cells treated with GArM and those not treated with GArM (Figure 18). By mixing GArM-treated HeLa cells with untreated HeLa cells, this characteristic was further accentuated, and two clearly defined peaks were observed.

[0147] Next, as a control experiment, we examined the binding ability of GArM using macrophages extracted from the peritoneal cavity of mice. Comparing the flow cytometry histograms (Figure 19), only slight differences were observed between macrophages with and without GArM, suggesting that, as expected, there was little or no binding ability.

[0148] In the final test to verify selectivity, we observed the combination of macrophages and HeLa cells incubated with or without the addition of GArM (Figure 20). In this experiment, we used the HeLa-V cell line expressing Venus (V) yellow fluorescent protein to distinguish between HeLa cells and macrophages. The flow cytometry profile clearly distinguishes Venus-expressing HeLa cells from macrophages. Upon addition of GArM, we found that most of the HeLa-V cells migrated to the upper right area, which represents GArM binding. On the other hand, no such change was observed in macrophages. As a result, this data strongly indicates that GArM can preferentially bind to HeLa cancer cells at the cellular level.

[0149] 8-4. Cell adhesion assay The ability of the SeCT-labeled reagent (GArM / cRGD-PE) to disrupt integrin-based cell adhesion was confirmed by an in vitro cell adhesion assay, which was performed using Human Fibronectin Coated 96-Well Microplates purchased from R&D System (Minneapolis, USA).

[0150] Adherent cells were quantified using a commercially available MTS assay, the CellTiter 96 Aqueous One Solution Cell Proliferation Assay (Promega). HeLa cells used in this experiment were made serum-free 16 h prior to the experiment by replacing the growth medium with DMEM (serum-free). Cells were then plated at 6x10 5The cells were subcultured to a concentration of 10 ... In a fibronectin-coated 96-well microplate, 130 μL of the labeled HeLa cell mixture was added to each well, and then the plate was incubated at 37°C for 10 min. After removing the medium, the attached cells were washed 3-4 times with PBS buffer solution. To remove nonspecifically bound cells, the PBS buffer solution was intermittently pipetted up and down. In the final step, 100 μL of DMEM (10% FBS + 1% penicillin-streptomycin) and 20 μL of MTS reagent were added. After 4 h of incubation at 37°C, the end-point absorbance at 490 nm was obtained using a SpectraMax iD3 mult-mode microplate reader (Molecular Devices, USA).

[0151] The results are shown in Figure 21. As expected, significant differences in cell adhesion on fibronectin-coated plates were observed for HeLa cells treated with SeCT labeling reagent (GArM / cRGD-PE). These differences were more evident, especially at higher treatment concentrations of cRGD-PE, indicating a higher concentration of catalytically bound cRGD on the cell surface.

Claims

1. A complex of a protein and a metal catalyst, The protein has a hydrophobic spot in its three-dimensional structure, the composite contains the catalyst within the hydrophobic spot such that the catalyst is not exposed or substantially not exposed to a hydrophilic environment; wherein the protein is human serum albumin (HSA); The hydrophobic spot of human serum albumin is albumin drug binding site I; The metal catalyst is bound to the hydrophobic spot via a coumarin. Complex.

2. 2. The composite of claim 1 , The metal catalyst is selected from the group consisting of boron catalyst, magnesium catalyst, aluminum catalyst, silicon catalyst, calcium catalyst, scandium catalyst, titanium catalyst, vanadium catalyst, chromium catalyst, manganese catalyst, iron catalyst, cobalt catalyst, nickel catalyst, copper catalyst, zinc catalyst, yttrium catalyst, zirconium catalyst, niobium catalyst, molybdenum catalyst, ruthenium catalyst, rhodium catalyst, palladium catalyst, silver catalyst, indium catalyst, tin catalyst, barium catalyst, hafnium catalyst, tungsten catalyst, rhenium catalyst, osmium catalyst, iridium catalyst, platinum catalyst, gold catalyst, and lanthanoid Lewis acid catalyst. Complex.

3. 3. The composite of claim 2, The lanthanide Lewis acid catalyst is selected from the group consisting of yttrium catalysts, lanthanum catalysts, cerium catalysts, samarium catalysts, europium catalysts, gadolinium catalysts, terbium catalysts, thulium catalysts, and lutetium catalysts. Complex.

4. The composite of claim 3, The metal catalyst is a ruthenium catalyst. Complex.

5. 2. The composite of claim 1 , The metal catalyst is attached to the hydrophobic spot via a linker attached to a coumarin. Complex.

6. 6. The composite of claim 5 , The linker is an alkyl chain or a polyethylene glycol (PEG) chain having an amino group and a carboxyl group at both ends. Complex.

7. 7. The composite of claim 6, The linker is 1 ~C 3 Alkyl Complex.

8. A composite according to any one of claims 1 to 7, The surface of the protein is modified to interact with a target site in vivo. Complex.

9. 9. The composite of claim 8, The modification is a modification with a sugar chain. Complex.

10. A composite according to any one of claims 1 to 7, The protein further comprises a portion that interacts with a target site in vivo. Complex.

11. A composition comprising the complex of any one of claims 1 to 10.